Abstract
T cell immunity is critical for a protective immune response against cancers. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. The lack of direct cytolytic effector function on part of CD4 T cells, which are MHC class II restricted, coupled with the MHC class II negative nature of most human cancers have been the main reasons for CD8 centered cancer immunotherapy approaches, so far. However, recent findings showing that CD4 T cells play an essential role towards the generation of a productive CD8 response and that the CD4 T cells can also play a direct role in anti-tumor immunity have resulted in growing enthusiasm towards engaging CD4 T cells in cancer immunotherapy. We here discuss the current approaches used for immune based cancer therapy, role of natural MHC class II-restricted CD4 T cells in tumor immunity, factors limiting the engagement of natural CD4 T cells in cancer immunotherapy protocols alongside CD8 T cells, and recent advances in TCR engineering approach to address these limitations. We will also discuss the significance of the MHC class I directed antitumor CD4 T cells in tumor immunity.
Keywords: Cancer, immunotherapy, MHC class I TCR engineered CD4 T cells
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy
Volume: 9 Issue: 4
Author(s): Arvind Chhabra
Affiliation:
Keywords: Cancer, immunotherapy, MHC class I TCR engineered CD4 T cells
Abstract: T cell immunity is critical for a protective immune response against cancers. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. The lack of direct cytolytic effector function on part of CD4 T cells, which are MHC class II restricted, coupled with the MHC class II negative nature of most human cancers have been the main reasons for CD8 centered cancer immunotherapy approaches, so far. However, recent findings showing that CD4 T cells play an essential role towards the generation of a productive CD8 response and that the CD4 T cells can also play a direct role in anti-tumor immunity have resulted in growing enthusiasm towards engaging CD4 T cells in cancer immunotherapy. We here discuss the current approaches used for immune based cancer therapy, role of natural MHC class II-restricted CD4 T cells in tumor immunity, factors limiting the engagement of natural CD4 T cells in cancer immunotherapy protocols alongside CD8 T cells, and recent advances in TCR engineering approach to address these limitations. We will also discuss the significance of the MHC class I directed antitumor CD4 T cells in tumor immunity.
Export Options
About this article
Cite this article as:
Chhabra Arvind, MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (4) . https://dx.doi.org/10.2174/187153009789839183
DOI https://dx.doi.org/10.2174/187153009789839183 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis
Mini-Reviews in Medicinal Chemistry Subject Index To Volune 2
Current Cancer Therapy Reviews Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Synthesis and <i>In Vitro</i> Cytotoxic Evaluation of Novel Murrayafoline A Derived β-Amino Alcohols
Letters in Organic Chemistry Targeting Epigenetic Modifiers in Cancer
Current Medicinal Chemistry Chemical and physical factors influencing the dynamics of differentiation in embryonic stem cells
Current Stem Cell Research & Therapy Marine Bromopyrrole Alkaloids: Synthesis and Diverse Medicinal Applications
Current Topics in Medicinal Chemistry Coronary Artery Bypass Graft in HIV-Infected Patients: A Multicenter Case Control Study
Current HIV Research Pharmacological Regulation of Human Eosinophil Apoptosis
Current Drug Targets - Inflammation & Allergy Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects
Current Cancer Drug Targets The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Gene Transfer and Drug Delivery with Electric Pulse Generators
Current Drug Metabolism Developments of Corey-Chaykovsky in Organic Reactions and Total Synthesis of Natural Products
Current Organic Synthesis Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Animal Models of Atherosclerosis Progression: Current Concepts
Current Drug Targets - Cardiovascular & Hematological Disorders